Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hertz

Showing results (321-330 of 368) with videos related to

Pageof 37
Sort By:
Breast Cancer Research and Treatment|March 14, 2020
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyTheodore S Jennaro, Fang Fang, Kelley M Kidwell, et al.
Cancer Treatment Reviews|June 26, 2021
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Daniel L Hertz, Daniel S Childs, Susanna B Park, et al.
JCO Precision Oncology|August 25, 2020
Integration of Germline Pharmacogenetics Into a Tumor Sequencing ProgramDaniel L Hertz, Andrew Glatz, Amy L Pasternak, et al.
Pharmacogenomics|December 7, 2018
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposureLauren A Marcath, Kelley M Kidwell, Adam C Robinson, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Clinical Genetics|October 19, 2010
The Renpenning syndrome spectrum: new clinical insights supported by 13 new PQBP1-mutated malesD Germanaud, M Rossi, G Bussy, et al.
Clinical and Translational Science|October 25, 2019
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working GroupKelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, et al.
Clinical Pharmacology and Therapeutics|January 31, 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeTeresa T Ho, D Max Smith, Christina L Aquilante, et al.
Pageof 37

Showing results (321-330 of 368) with videos related to

Sort By:
Pageof 37
Breast Cancer Research and Treatment|March 14, 2020
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyTheodore S Jennaro, Fang Fang, Kelley M Kidwell, et al.
Cancer Treatment Reviews|June 26, 2021
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Daniel L Hertz, Daniel S Childs, Susanna B Park, et al.
JCO Precision Oncology|August 25, 2020
Integration of Germline Pharmacogenetics Into a Tumor Sequencing ProgramDaniel L Hertz, Andrew Glatz, Amy L Pasternak, et al.
Pharmacogenomics|December 7, 2018
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposureLauren A Marcath, Kelley M Kidwell, Adam C Robinson, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Clinical Genetics|October 19, 2010
The Renpenning syndrome spectrum: new clinical insights supported by 13 new PQBP1-mutated malesD Germanaud, M Rossi, G Bussy, et al.
Clinical and Translational Science|October 25, 2019
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working GroupKelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, et al.
Clinical Pharmacology and Therapeutics|January 31, 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeTeresa T Ho, D Max Smith, Christina L Aquilante, et al.
Pageof 37